Peptide · Fact sheet

Kisspeptin

Also known as kisspeptin-54 · kisspeptin-10 · metastin

Kisspeptin can activate reproductive-hormone signaling in people and has been studied as an egg-maturation trigger in IVF research. It is not FDA approved for fertility, libido, testosterone, mood, or other consumer uses.

In clinical trialsEarly human evidence

What is Kisspeptin?

Kisspeptins are related peptides made from the KISS1 protein. They stimulate gonadotropin-releasing hormone neurons and sit near the top of the reproductive hormone cascade.

Kisspeptin-54 and kisspeptin-10 differ in length and exposure; findings from one formulation or setting should not be silently applied to another.

Benefits & claims

Human studies have examined hormone release, puberty biology, IVF egg maturation, sexual and emotional brain processing, and reproductive disorders.

Changing a hormone signal is not the same as proving better fertility, sexual function, mood, or long-term health.

What the evidence supports

  • A completed Phase 2 program showed that kisspeptin-54 could produce mature eggs in selected people undergoing IVF.
  • Human crossover studies demonstrate short-term effects on luteinizing hormone and some brain-response measures, not proven fertility or mental-health benefits.
Research areas
  • Egg maturation during IVF
  • Reproductive hormone release
  • Hypothalamic amenorrhea and other reproductive disorders
  • Sexual and emotional brain processing
  • Triggering egg maturation in selected IVF settings
  • Diagnosing or treating reproductive hormone disorders
  • Neuroendocrine and behavioral research

Dosage & frequency

No established human regimen

Human reproductive studies use tightly timed study protocols. There is no established FDA-approved kisspeptin regimen for general hormone optimization.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Kisspeptin-54 and shorter kisspeptin fragments are different research formulations.

Interactions & precautions

  • Reproductive-study protocols do not establish compatibility with unsupervised hormone combinations or every fertility medicine.

What is still unresolved

  • A broadly effective outpatient treatment schedule and long-term reproductive safety remain unresolved.

Side effects & risks

  • Short-term research has not established a complete safety profile for repeated or broader use.
  • FDA identifies potential immune reactions, peptide impurities, and limited route-specific safety information for compounded kisspeptin-10.
  • Changing reproductive-hormone signaling may create different risks across sex, age, pregnancy status, and endocrine conditions.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

Controlled human studies confirm reproductive-hormone effects and show that kisspeptin-54 can trigger egg maturation in selected IVF research populations. Larger comparative trials and long-term outcomes remain limited.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Pain: reported experiences

Mixed account · personal report

Better sexual function, other symptoms unchanged

A longer follow-up described restored sexual desire and erections but persistent testicular pain and urinary sensations. The stronger desire was sometimes distracting.

Reported use in this account

Product
Product described as kisspeptin-10
Amount
66.6 micrograms
Frequency
Once daily at the initial update
Route
Intranasal
Duration
About one month and one week at the initial update

Other exposures described: Testosterone replacement stopped before the report; Pregnenolone and progesterone added in a later follow-up

The author had recently stopped testosterone and later mentioned progesterone. Symptoms fluctuated, and the product and recovery were not clinically verified.

Read the original account

Approval status

Kisspeptin has no FDA-approved drug product. Human research includes completed Phase 2 IVF studies, while FDA has described limited safety information and potential peptide-quality concerns for compounded kisspeptin-10.

Early to mid-stage reproductive research

Kisspeptin has human Phase 2 research in IVF-related triggering, but it has no FDA-approved product or broad reproductive, mood, or wellness indication.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether it improves live-birth outcomes compared with established IVF approaches
  • Long-term reproductive and metabolic safety
  • Which formulation and patient groups, if any, offer a favorable benefit-risk balance
  • Whether brain-imaging or hormone changes translate into meaningful daily-life outcomes

Summary

Kisspeptin has human physiology and IVF research but remains investigational. Hormone changes alone do not establish fertility or sexual benefits.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. clinical trialsClinicalTrials.gov: kisspeptin in IVF

    Completed Phase 2 study with public results on egg maturation during IVF.

  2. pubmedKisspeptin-54 egg-maturation study

    Human study of kisspeptin-54 as an egg-maturation trigger.

  3. pubmedRandomized study of sexual and emotional brain processing

    Controlled human mechanistic study that does not establish a therapeutic benefit.

  4. fdaFDA: safety risks for selected compounded bulk substances

    FDA's current substance-specific summary of evidence gaps and potential safety risks.

How we assess sources · Suggest a correction